These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 20082116)

  • 21. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
    Raymond E; Alexandre J; Faivre S; Goldwasser F; Besse-Hammer T; Gianella-Borradori A; Jego V; Trandafir L; Rejeb N; Awada A
    Invest New Drugs; 2014 Feb; 32(1):94-103. PubMed ID: 23539344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.
    Nowakowski GS; McCollum AK; Ames MM; Mandrekar SJ; Reid JM; Adjei AA; Toft DO; Safgren SL; Erlichman C
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6087-93. PubMed ID: 17062684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
    Attia S; Morgan-Meadows S; Holen KD; Bailey HH; Eickhoff JC; Schelman WR; Traynor AM; Mulkerin DL; Campbell TC; McFarland TA; Huie MS; Cleary JF; Tevaarwerk AJ; Alberti DB; Wilding G; Liu G
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):45-51. PubMed ID: 18841362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
    Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
    O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
    Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
    Ramalingam SS; Egorin MJ; Ramanathan RK; Remick SC; Sikorski RP; Lagattuta TF; Chatta GS; Friedland DM; Stoller RG; Potter DM; Ivy SP; Belani CP
    Clin Cancer Res; 2008 Jun; 14(11):3456-61. PubMed ID: 18519777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.
    Hiret S; Isambert N; Gomez-Roca C; Bennouna J; Sassi M; de Mont-Serrat H; Fan J; Schnell D; Delord JP
    Invest New Drugs; 2018 Dec; 36(6):1044-1059. PubMed ID: 29808308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
    Ryan DP; Appleman LJ; Lynch T; Supko JG; Fidias P; Clark JW; Fishman M; Zhu AX; Enzinger PC; Kashala O; Cusack J; Eder JP
    Cancer; 2006 Nov; 107(10):2482-9. PubMed ID: 17036355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
    Schelman W; Morgan-Meadows S; Bailey H; Holen K; Thomas JP; Eickhoff J; Brandon H; Oliver K; Alberti D; Wilding G
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):727-33. PubMed ID: 18172649
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
    Angevin E; Cassier PA; Italiano A; Gonçalves A; Gazzah A; Terret C; Toulmonde M; Gravis G; Varga A; Parlavecchio C; Paci A; Poinsignon V; Soria JC; Drubay D; Hollebecque A
    Eur J Cancer; 2017 Sep; 83():194-202. PubMed ID: 28750271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
    Fountzilas C; Adjei A; Opyrchal M; Evans R; Ghasemi M; Attwood K; Groman A; Bshara W; Goey A; Wilton J; Ma WW; Iyer R
    Int J Cancer; 2021 Dec; 149(12):2063-2074. PubMed ID: 34319586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
    Rixe O; Puzanov I; LoRusso PM; Cohen RB; Morris JC; Olowokure OO; Yin JY; Doroumian S; Shen L; Olszanski AJ
    Anticancer Drugs; 2015 Aug; 26(7):785-92. PubMed ID: 26020806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
    Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
    Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
    Costello BA; Borad MJ; Qi Y; Kim GP; Northfelt DW; Erlichman C; Alberts SR
    Invest New Drugs; 2014 Aug; 32(4):710-6. PubMed ID: 24740268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.
    Subbiah V; Grilley-Olson JE; Combest AJ; Sharma N; Tran RH; Bobe I; Osada A; Takahashi K; Balkissoon J; Camp A; Masada A; Reitsma DJ; Bazhenova LA
    Clin Cancer Res; 2018 Jan; 24(1):43-51. PubMed ID: 29030354
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.